Clinical Trials

Search Form

Disease Site Trial Sort descending Trial Description Trial Status Lead Cooperative Group
Recurrent Cervical GOG 240

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer 

Completed GOG-F
Recurrent Endometrial ENGOT-EN1 / NSGO- FANDANGO

ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer 

Completed NSGO-CTU
Recurrent Endometrial GOG 0238

Radiation Therapy with or without Cisplatin in Treating Patients with Recurrent Endometrial Cancer

Recruiting GOG-F
Recurrent Maintenance Ovarian ICON9

An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Closed to Recruitment NCRI
Recurrent Ovarian AGO-OVAR 2.21

A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carbolatin/pegylated liposomal doxorubin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer 

Completed AGO
Recurrent Ovarian AGO-OVAR 2.29

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Follow Up AGO
Recurrent Ovarian AGO-OVAR OP.4/DESKTOP III

A randomized trial evaluating cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer

Completed AGO
Recurrent Ovarian ATALANTE

Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

Completed GINECO
Recurrent Ovarian ENGOT-ov50/GOG-3029/INNOVATE-3

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

Closed to Recruitment BGOG
Recurrent Ovarian GOG 0213

Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Recruiting GOG-F
Recurrent Ovarian ICON6

A randomised trial of concurrent cediranib [AZD2171] (with platinum-based chemotherapy) and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer. 

Completed NCRI
Recurrent Ovarian INOVATYON

Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum

Completed MaNGO
Recurrent Ovarian KGOG 3045/ AMBITION

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer

Closed to Recruitment KGOG
Recurrent Ovarian KGOG 3056 / NIRVANA-R

A single-arm phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive ovarian cancer patients previously treated with a PARP inhibitor 

Recruiting KGOG
Recurrent Ovarian KGOG 3064/ KROG 2204/ SABR-ROC

Prospective Multi-institutional Phase III Trial of Salvage Systemic Therapy with or without Stereotactic Ablative Radiation Therapy for Recurrent Ovarian Cancer

Recruiting KGOG
Recurrent Ovarian MITO8

Liposomal doxorubicin stealth vs. carboplatin/paclitaxel in recurrent ovarian cancer patients with platinum-free interval between 6-12 months 

Completed MITO
Recurrent Ovarian OReO-ENGOT-Ov38 (ENGOT/GCIG/AZ)

Phase III study Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer

Closed to Recruitment GINECO
Recurrent Ovarian SOLO-2 (ENGOT-GCIG/AstraZeneca)

Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenence Monotherapy in Platinum Sensitive relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy

Completed GINECO
Recurrent Ovarian/Rare NiCCC

A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

Closed to Recruitment SGCTG
Symptom Benefit ENGOT -gyn4/ NOGGO S20/ Expression IX

Long-term survival with gynecological cancer

Recruiting NOGGO